Dr. Manthan Mehta’s Post

𝐇𝐨𝐰 𝐚𝐫𝐞 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐛𝐞𝐜𝐨𝐦𝐢𝐧𝐠 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐥 𝐭𝐨 𝐦𝐨𝐝𝐞𝐫𝐧 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬? Digital therapeutics represent a burgeoning field that is reshaping the landscape of patient care through technology-driven treatments. As I connect healthcare facilities with top IT talent, I've observed how digital therapeutics are becoming integral to modern healthcare strategies: 📱 Tailored Treatment Options: Digital therapeutics offer personalized treatments based on patient data and behavior, enabling more precise and effective care. These treatments can be adjusted in real time, responding to patient needs as they evolve. 🧠 Mental Health Innovations: Particularly impactful in the realm of mental health, digital therapeutic platforms provide cognitive behavioral therapies and other psychological supports, accessible from the comfort of a patient's home. 📊 Chronic Disease Management: For chronic conditions like diabetes or hypertension, digital therapeutics provide continuous monitoring and lifestyle management tools that help patients manage their health daily. 💊 Integration with Traditional Therapies: Digital therapeutics are often used in conjunction with pharmaceutical treatments, enhancing drug efficacy and patient adherence through medication reminders and educational content. 🔍 Outcome Tracking and Improvement: These technologies enable real-time tracking of patient outcomes, facilitating immediate adjustments to treatment plans and providing valuable data to healthcare providers for improved decision-making. 🌍 Accessibility and Scalability: By leveraging the internet and mobile technology, digital therapeutics can reach a broader audience, including underserved populations who might not have access to traditional healthcare services. 🌟 The integration of digital therapeutics into patient care is not just an enhancement; it's a revolution, offering new, efficient, and more accessible methods for disease prevention, management, and treatment. If you're involved in the development or implementation of digital therapeutics, or if you're interested in how these tools can be integrated into broader healthcare practices, let's connect. Together, we can explore the potential of digital therapeutics to transform patient care for the better. #DigitalTherapeutics #PatientCare #HealthcareInnovation #DigitalHealth #ChronicDiseaseManagement

The integration of digital technologies in treating rare diseases is significantly transforming patient care, offering new hopes and extending the possibilities within healthcare. Innovations in data analytics and artificial intelligence are proving crucial in improving diagnostic capabilities, enhancing research and development, and optimizing patient identification and monitoring of disease progression. These advancements are facilitating a shift towards more personalized medicine, particularly for conditions like Duchenne Muscular Dystrophy (DMD) where new therapies are extending life significantly beyond previous expectations. The industry's focus on rare diseases has been further invigorated by legislative support like the Orphan Drug Act, encouraging pharmaceutical companies to invest in and develop treatments for these less common ailments. However, despite the technological advances and market growth, challenges remain, particularly due to the small patient populations typical of rare diseases which require highly individualized treatment approaches. The rise of digital technologies offers promising solutions, such as sophisticated patient-centric models that utilize analytics to tailor treatments and improve engagement with healthcare providers and patients. Companies are leveraging these tools to better navigate extensive datasets, allowing for more precise and effective patient care strategies. With these developments, the pharmaceutical industry is not only addressing the immediate health needs but is also reshaping its approach to rare disease treatment, making a significant impact on both the market and the individuals it serves. https://lnkd.in/e--ZaM6A

Digital Therapeutics (DTx) Market Set for Rapid Growth! The digital therapeutics (DTx) market is on a fast track, projected to grow at a remarkable CAGR of 25-27% from 2024 to 2029. This surge is driven by several key factors: 🔹 Rising prevalence of chronic diseases 🔹 Increased adoption of smartphones and digital health tools 🔹 Growing demand for personalized healthcare solutions 🔹 Supportive regulatory frameworks 🔹 Heightened awareness around preventive care Despite these growth drivers, the industry faces challenges, including regulatory hurdles, data privacy concerns, and limited reimbursement options, which may impact expansion. The market features a range of innovative players, from established companies to emerging leaders, such as Omada Health, Welldoc, 2Morrow,, Teladoc Health, Propeller Health, ResMed, Canary Health, Noom, Akili, Big Health, and Mango Health Key strategies driving the market forward include product innovation, strategic partnerships, and geographic expansion. 📈 Curious to dive deeper? Download the sample report brochure here: https://lnkd.in/dvbJP_pU

At RNT Health Insights, we are thrilled to announce our emergence from stealth mode with the achievement of a significant milestone: our Early Gastric Cancer detection technology has been granted the prestigious Breakthrough Device Designation by the US Food and Drug Administration (FDA). Gastric cancer remains a major global health challenge, being the fourth leading cause of cancer-related mortality, with a five-year survival rate of less than 40%. Early and accurate detection can increase this rate to 90%. Despite being the gold standard, Gastrointestinal endoscopic procedures have a miss rate of 4.6-25.8% for gastric cancers, depending on the endoscopist’s experience. Our Early Gastric Cancer detection technology, with a detection accuracy of 96% based on preclinical validation, aims to significantly improve diagnostic accuracy during real-time endoscopic procedures. This designation is a testament to our innovative solution designed to detect lesions indicative of Early Gastric Cancer, as well as associated malignant lesions, in real-time during standard endoscopy examinations. This recognition highlights the potential of our technology to significantly advance the diagnosis of life-threatening conditions, providing timely and accurate detection that could greatly improve patient outcomes. The Breakthrough Device Designation not only highlights the clinical potential of our technology but also provides an accelerated regulatory pathway, allowing us to expedite our device development and bring our life-saving innovation to market more quickly. For more details, please refer to the following featured press releases: Business Standard: https://lnkd.in/ggfJustc The Print: https://lnkd.in/gGKkimpf Press Trust of India: https://lnkd.in/gfXQcSca Business Wire India: https://lnkd.in/gJ5xSzY6 Kalkine Media: https://lnkd.in/gFkcaynd Stay tuned for more updates. RNT Health Insights | Tanmaya Gulati | Ria Khurana | IKP EDEN | MedTech Innovator | MedTech Innovator Asia Pacific

Digital Therapeutics (DTx) Product Assessment Frameworks DTx are transforming the healthcare sector by offering software-based treatments that extend beyond conventional therapeutic approaches, marking a significant shift towards more personalized, accessible, and evidence-driven care. The unique nature of DTx, leveraging software algorithms, user interfaces, and engagement strategies, presents distinct challenges in assessing their effectiveness, safety, and impact on health outcomes. As such, there's a critical need for standardized frameworks to thoroughly evaluate DTx products, addressing these challenges and ensuring their integration into healthcare systems enhances patient care. The development of specialized assessment methodologies tailored to the digital and innovative aspects of DTx is essential. Incorporating DTx into existing Health Technology Assessment (HTA) frameworks, and adapting to new sources of evidence, will be key in overcoming these challenges, facilitating their evaluation, and maximizing their potential to improve patient outcomes. These frameworks are based on the following references: Digital Therapeutics Alliance DTx Value Assessment & Integration Guide: https://lnkd.in/dQfbdvFJ Peterson Health Technology Institute (PHTI) Assessment Framework for Digital Health Technologies: https://lnkd.in/dYPTg39i Invitation to review: Dhaval Desai, Matt Perrine, Johannes Boshkow, Emilie Lopes-Fernandes, Varun Ramdevan, Stephen Hamm, MBA, Yoann Sapanel, Scott Kellogg, Lisa Britton, MBA, Przemek Grzywa, Marguerite Manteau-Rao, LCSW, MBA, James Faux, MBA, Wes Hassan, Emanuela Kufel, Bruce Imbert MD, PhD, MPH, Abby (Captain) Doctolero, Patrick Candela, Hakim Yadi Ph.D. OBE, Ryan Douglas, Rick Bartels, MBA, Evans D. Pope, III, Brian Harris, Ed Furlong, Darren R Hocking, Ph.D., Shijun Jo, Klaudia Grzeszczak, Kalyan Kalwa, Robert A., Renata Redondo Bonaldi, PhD, Global MBA, Jessica Ackerman MS,CCC-SLP, Haresh Keswani, William Walters, Rudolf Wagner, Devanathan Raghunathan PhD MBA #healthcare #digitalhealth #healthinnovation #digitaltherapeutics #assessment

🚀 We are very excited about the results and product progress for Koios Care arm to revolutionise clinical research with #passivesensing validated machine learning and #genai! 🚀 We are excited to announce that Koios Care is leading the way in applying multimodal #generativeai to passively sensed data in clinical research! One of our breakthroughs is our ability to measure a range of novel activities related to Quality of Life (e.g., vomiting, nausea or improved mobility at home) and get timely patient feedback. We use a combination of passive sensing and symptom/side-effect-triggered PROs to overcome recall bias and capture the true patient experience. 📈 Improving Treatment Effectiveness Evaluation: At Koios Care, we understand that treatment effectiveness is the ultimate goal and clinical assessments are limited. Our cutting-edge passive sensing tools and AI enable us to evaluate quality of life and treatment responses more objectively and comprehensively. By leveraging real-world data from commercial devices, we reveal how therapies affect patients’ lives. This knowledge informs evidence-based medicine and enhances patient care. 🔎 Detecting Side Effects with Accuracy By continuously tracking adverse events-related signs such as vomiting and toilet flushes, patients can promptly report these events to enable researchers and healthcare professionals to make informed decisions. A data-driven approach ensures patient safety and supports the overall success of clinical trials. Follow us for updates, insights, and innovations! #ClinicalResearch #HealthcareInnovation #PatientSafety #DataDrivenHealthcare #KoiosCare 👋 If you are in the area of developing new drugs (Parkinson’s disease, antibiotics, Nonsteroidal anti-inflammatory drugs, chemotherapy drugs, Opioids, Antidepressants, Blood pressure drugs) and you are interested in capturing patients’ quality of life digital measures using passive digital tools for long-term patient adherence in your clinical trials, we would love to hear from you!

We closely examine the future of digital therapeutics and healthcare regulation in Southeast Asia and what it means for the industry.

2028 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐒𝐢𝐳𝐞 & 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 Download PDF Brochure @ https://lnkd.in/d8-5tyFw The 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 21.9 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 𝐟𝐫𝐨𝐦 𝐔𝐒𝐃 6.1 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023, 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 29.1% during the forecast period. Despite the availability of highly effective and low-cost treatment options for chronic disorders, a large undiagnosed and untreated population still exists. According to the 𝐖𝐇𝐎, many people affected by chronic diseases do not get the required treatment and care. According to WHO, in 2019, over one billion people with hypertension (82% of all people with hypertension worldwide) lived in low and middle-income countries. According to 𝐁𝐌𝐂 𝐏𝐮𝐛𝐥𝐢𝐜 𝐡𝐞𝐚𝐥𝐭𝐡 𝐉𝐨𝐮𝐫𝐧𝐚𝐥 2022, the 𝐨𝐯𝐞𝐫𝐚𝐥𝐥 𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐫𝐚𝐭𝐞𝐬 𝐨𝐟 𝐮𝐧𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝, 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝, 𝐚𝐧𝐝 𝐮𝐧𝐝𝐞𝐫𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐡𝐲𝐩𝐞𝐫𝐭𝐞𝐧𝐬𝐢𝐨𝐧 𝐚𝐦𝐨𝐧𝐠 𝐨𝐥𝐝𝐞𝐫 𝐚𝐝𝐮𝐥𝐭𝐬 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚 𝐰𝐞𝐫𝐞 42.3%, 6%, 𝐚𝐧𝐝 18.7%, 𝐫𝐞𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞𝐥𝐲. 𝐀𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 90% 𝐨𝐟 𝐂𝐎𝐏𝐃 𝐝𝐞𝐚𝐭𝐡𝐬 𝐨𝐜𝐜𝐮𝐫 𝐢𝐧 𝐥𝐨𝐰 𝐚𝐧𝐝 𝐦𝐢𝐝𝐝𝐥𝐞-𝐢𝐧𝐜𝐨𝐦𝐞 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬, 𝐚𝐬 𝐭𝐡𝐞𝐲 𝐝𝐨 𝐧𝐨𝐭 𝐠𝐞𝐭 𝐭𝐡𝐞 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭. 𝐎𝐯𝐞𝐫 75% 𝐨𝐟 𝐂𝐕𝐃-𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐞𝐚𝐭𝐡𝐬 𝐨𝐜𝐜𝐮𝐫 𝐢𝐧 𝐥𝐨𝐰 𝐚𝐧𝐝 𝐦𝐢𝐝𝐝𝐥𝐞-𝐢𝐧𝐜𝐨𝐦𝐞 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬, 𝐩𝐫𝐢𝐦𝐚𝐫𝐢𝐥𝐲 𝐝𝐮𝐞 𝐭𝐨 𝐥𝐨𝐰/𝐥𝐢𝐦𝐢𝐭𝐞𝐝 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐚𝐩𝐩𝐫𝐨𝐩𝐫𝐢𝐚𝐭𝐞 𝐜𝐚𝐫𝐞. Often, treatment for these conditions is not integrated into primary healthcare—the only access to medical care across these regions. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Digital Therapeutics Alliance Centre for Digital Therapeutics    Curio Digital Therapeutics Inc.     TupeloLife Digital Therapeutics   Click Therapeutics, Inc.      Better Therapeutics Virgin Pulse Kaia Health      Lupin Digital Health     DarioHealth    Glooko Proxima CRO   Xealth MedRhythms, Inc. RealizedCare     SPRIM PRO  Human API    Care Innovations®     Blue Note Therapeutics      Avegen MindMaze     HTD Health     Fitterfly Resolute (HumanFractal.Ai)    Rx.Health (Commure Engage)  Noom, Teladoc Health, Omada Health, Welldoc,

💊 𝗗𝗿𝘂𝗴 + 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗮𝘀 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗼𝗳 𝗖𝗮𝗿𝗲? 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗔𝗰𝗵𝗶𝗲𝘃𝗶𝗻𝗴 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝘄𝗶𝘁𝗵 𝗗𝗧𝘅 𝗗𝗿𝘂𝗴 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 Join us at the 𝟰𝘁𝗵 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 on November 7-8 in 𝗟𝗶𝘀𝗯𝗼𝗻 and learn from Pete Brockmeier, Global Associate Director, Digital Health, Novo Nordisk. Across many industries, modern products include a digital component, enabling personalization, enhanced experiences, and generating valuable data for customers and companies. In medicine, “drug + digital" offerings can similarly improve patient experiences and outcomes, leveraging clinically validated DTx companion apps to simplify and optimize medication use. However, the adoption of these solutions has been challenged by regulatory and distribution complexities and unclear or lacking incentives for key stakeholders in the value chain. Pete's talk will explore practical strategies to overcome these hurdles and effectively deliver DTx drug companion apps to patients, unlocking their potential benefits. At the 4th Digital Health Conference in Lisbon, you will also learn from speakers: 🎤 Ghaith Sankari, Head of Global Digital Health Data Science, Bayer 🎤 Paula Salme Sandrak, Product Strategist (dHealth & Health AI), Bayer 🎤 Dr. Jochen Hurlebaus, Head Digital Health Innovation, Roche Information Solutions 🎤 Dr. Ricardo Sáinz Fuertes, Global Director Digital Health Solutions NEURii Program Director, Eisai EMEA 🎤 Sridevi Nagarajan, Head Digital Regulatory Strategy, AstraZeneca 🎤 Lu Zheng, Head of Value-Based Partnerships and Digital Health, Europe & Canada, Takeda 🎤 Dan Ma, Head of Innovation & New Commercial Partnerships, Sandoz 🎤 Ayaka Yanagisawa, Former Head of Data Analytics, Biogen 🎤 Gemma Malla Salomó, Head of Digital Medicines Iberia & Business Unit Head Ophthalmology, Angelini Pharma 🎤 Leslie Anne Fendt, Integrated Solutions Program Lead, Remote Vision Monitoring (myVisionTrack / mVT(x) / Home Vision Monitor), Roche 🎤 Pete Brockmeier, Global Associate Director, Digital Health, Novo Nordisk 🎤 Miguel Amador, Partner and Chief Innovation Officer, Complear 🎤 Charlotte S., Senior Digital Health Scientist, Lundbeck 🎤Julia Chernova, Associate Director, Clinical Statistics and Digital Health, Bayer and others... Gain insights from industry leaders and explore how to navigate the evolving landscape of digital health to achieve meaningful impact and sustainable advancements in patient care. 📍 𝗔𝗹𝘁𝗶𝘀 𝗚𝗿𝗮𝗻𝗱 𝗛𝗼𝘁𝗲𝗹, 𝗟𝗶𝘀𝗯𝗼𝗻 📆 7-8 November 2024 💺 Limited to 100 seats for optimal networking ➡ Register here https://lnkd.in/d8GG8RkM ⏰  𝟰𝟴 𝗵𝗼𝘂𝗿𝘀 𝗳𝗼𝗿 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝗧𝗶𝗰𝗸𝗲𝘁𝘀, 𝗱𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗶𝘀 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆!⏰ #DigitalHealth #Dtx #𝗗𝗛𝗨𝗕𝗜𝗤 Be part of the revolution in healthcare! See you in Lisbon!

Digital Therapeutics: The Future of Personalized, Accessible Healthcare... Digital therapeutics (DTx) refers to software-driven treatments that deliver evidence-based interventions to prevent, manage, or treat medical conditions. These therapies are often used in conjunction with medications or as stand-alone solutions, focusing on behavioral, mental health, and chronic disease management. DTx leverages technologies like 📌 mobile apps, 📌 AI, and 📌 wearable/connected devices to personalize care and provide real-time feedback to patients. In the future, digital therapeutics is expected to revolutionize healthcare by making treatments more accessible, improving patient adherence, and lowering costs. By collecting vast amounts of health data, DTx can enable more precise, individualized care, reduce hospital readmissions, and enhance preventive medicine. This shift could democratize access to high-quality healthcare, especially for those in remote or underserved areas, ultimately improving patient outcomes on a global scale. Download Deloitte's free report on digital therapeutics here: https://lnkd.in/eiHKS63h